Skip to main content

Clinical Trials Using Carboplatin

Review the clinical trials studying carboplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 266

Neoadjuvant Response-Adapted Chemotherapy with Pembrolizumab for the Treatment of Patients with Stage 2 and 3 Triple Negative Breast Cancer
Status: Active
Location: 3 locations
Carboplatin or Cisplatin, Etoposide, and Durvalumab with Hypofractionated Ablative Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, DARES Study
Status: Active
Location: 3 locations
Neoadjuvant Cemiplimab with Histology-Specific Chemotherapy Followed by Surgery and Adjuvant Cemiplimab for the Treatment of Locally Advanced Non-Small Cell Lung Cancer, NEO-SURG Trial
Status: Active
Location: 3 locations
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Status: Active
Location: 5 locations
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Status: Active
Location: 4 locations
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: 3 locations
Carboplatin and 177Lu-PSMA-617 for the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer, LuCarbo Trial
Status: Active
Location: 3 locations
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Status: Active
Location: 2 locations
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Status: Active
Location: 2 locations
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Status: Active
Location: 2 locations
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 5 locations
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Status: Active
Location: 5 locations
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Status: Active
Location: 3 locations
Sotorasib, Cisplatin or Carboplatin, and Pemetrexed for the Treatment of Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS p.G12C Mutation
Status: Active
Location: 2 locations
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Status: Active
Location: 2 locations
Pembrolizumab and Chemotherapy before Surgery followed by Pembrolizumab after Surgery for the Treatment of Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Ascorbic Acid with Gemcitabine and Carboplatin for Treating Patients with Muscle Invasive Bladder Cancer
Status: Active
Location: 2 locations
Personalized Treatment following Chemoradiotherapy and Immunotherapy for the Treatment of Stage III Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Status: Active
Location: 2 locations
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
Status: Active
Location: 2 locations
Immunotherapy with or without Chemotherapy for the Treatment of Metastatic or Unresectable Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Toripalimab, Carboplatin and Docetaxel for the Treatment of Stage III-IVB Sinonasal Cancer before Surgery
Status: Active
Location: 2 locations
Restorative Microbiota Therapy in Combination with Durvalumab, Tremelimumab, and Chemotherapy for the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Atezolizumab with Cisplatin or Carboplatin and Etoposide Followed by Cystectomy for the Treatment of Patients with Localized Small Cell Neuroendocrine Bladder Cancer
Status: Active
Location: 2 locations